SUNA SOCIETY OF UROLOGIC

PATIENT EDUCATION PROCEDURE HANDOUT

Onabotulinumtoxin A (Botox)

SUNA Postoperative Care Task Force

Overview

Onabotulinumtoxin A (Botox) treatment involves putting a small telescope (cystoscope) into the bladder to perform a bladder wall injection. The procedure takes about 10 to 15 minutes to complete. Onabotulinumtoxin A (Botox) works by stopping nerve impulses to the bladder muscle for temporary relaxation. When injected into specific areas of the bladder, Onabotulinumtoxin A (Botox) can stop bladder contractions to allow for more normal flow of urine.

Indications

Onabotulinumtoxin A (Botox) injections are a treatment for severe bladder symptoms, such as severe urgency, inability to delay urination, and urinary sphincter spasm. It works by stopping some nerves in the bladder or sphincter muscles.

What to Expect Before the Procedure

- You may be asked to stop taking any blood thinners, aspirin, or anti-inflammatory medications prior to the procedure. Please tell your urologist if you take any of these medications.
- Please tell your urologist if you are allergic to any medications, latex, iodine, tape, contrast dye, or anesthesia.
- You will be asked not to eat or drink anything after midnight on the evening before your procedure.
- Please arrange for a ride home. You will not be able to drive yourself home after the procedure.

What to Expect After the Procedure

Diet: You may return to your regular diet. You may experience some mild nausea and possible vomiting for the first 6 to 8 hours after surgery. Drink clear liquids and eat a light meal first night following surgery. Drink a lot of fluids to help reduce any bleeding and pain.

Activity: Do not lift more than 10 pounds for 1 to 2 days.

Driving: Do not drive for 24 hours after receiving sedation.

Urinating: There may be some pain, burning, urgency, frequency, and blood-colored urine following the procedure. These symptoms usually resolve in 2 to 5 days. In some cases, you may be unable to urinate, so you may need to use a self-catheter.

Complications

Complications may include:

- Bleeding.
- Infection.
- Pain and discomfort.
- Difficulty urinating (you may need a catheter).

When to Call the Clinic

Please call the clinic if you experience any of the following:

- Fever or chills (greater than 100.4 degrees F). This may be a sign of an infection.
- Pain that is not controlled with medication.
- If you are unable to urinate.
- · Severe bleeding.

**If you are unable to reach the office and are in need of immediate assistance, please proceed to the nearest Emergency Department.

Acknowledgment

We would like to especially thank the following SUNA members for their valuable contributions to these special focus issues. They either acted as a peer reviewer, author of the educational handouts, or both.

Michele Boyd, MSN, RN, NPD-BC Lynn Huck, ANP

Christopher T. Tucci, MS, RN, BC, CURN, NE-BC, FAUNA

Gwendolyn Hooper, PhD, APRN, CUNP Anthony R. Lutz, MSN, NP-C, CUNP

Margaret (Amy) Hull, DNP WHNP-BC

Annemarie Dowling-Castronovo, PhD, RN, GNP-BC, ACHPN

Lais Heideman, RN, CURN

Susanne A. Quallich, PhD, ANP-BC, NP-C, CUNP, FAUNA, FAANP

Michelle J. Lajiness, FNP-BC, FAUNA Marc M. Crisenbery, MSN, APRN, FNP-BC

We hope you and all your family members may benefit from these handouts.

Resources

- American Urological Association. (2019). *Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults:*An AUA/SUFU guideline. https://www.auanet.org/guidelines/guidelines/overactive-bladder-(oab)-guideline#x3763
- Gormley, E.A., Lightner, D.J., Burgio, K.L. Chai, T.C., Clemens, J.Q., Culkin, D.J., Das, A.K., Foster, Jr., H.E., Scarpero, H.M., Tessier, C.D., Vasavada, S.P., American Urological Association, & the Society of Urodynamics, Female Pelvic Medicine, & Urogenital Reconstruction. (2012). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Journal of Urology, 188(Suppl. 6), 2455-2463.
- Lightner, D.J., Gomelsky, A., Souter, L., & Vasavada, S.P. (2019). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. Journal of Urology, 202(3), 558-563.
- López Ramos, H., Torres Castellanos, L., Ponce Esparza, I., Jaramillo, A., Rodríguez, A., & Moreno Bencardino, C. (2017). Management of overactive bladder with onabotulinumtoxinA: Systematic review and meta-analysis. *Urology*, 100, 53-58. https://doi.org/10.1016/j.urology.2016. 10.026
- Urology Care Foundation. (n.d.). Insights: Use of Botox® in urology. https://www.urologyhealth.org/healthy-living/urologyhealth-extra/magazine-archives/fall-2019/insights-use-of-botox%C2%AE-in-urology

This material is for educational purposes only and should in no way be taken to be the practice or provision of medical, nursing or professional healthcare advice or services. The information should not be used in place of a visit, call, consultation or advice of your physician, nurse or other health care provider. The information obtained herein is not exhaustive and does not cover all aspects of the specific disease, ailment, physical condition or their treatments. Should you have any health care related questions, please call or see your physician, nurse or other health care provider promptly.

The Society of Urologic Nurses and Associates, Inc. is a professional organization committed to excellence in patient care standards and a continuum of quality care, clinical practice, and research through education of its members, patients, family, and community.

© 2022 Society of Urologic Nurses and Associates